AQR Capital Management
DSGN icon

AQR Capital Management’s Design Therapeutics DSGN Stock Holding History

AQR Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
71,114
+45,157
+174% +$563K ﹤0.01% 2989
2026
Q1 		$276K Buy
25,957
+12,227
+89% +$124K ﹤0.01% 3445
2025
Q4 		$129K Buy
13,730
+66
+0.5% +$517 ﹤0.01% 3442
2025
Q3 		$103K Sell
13,664
-15,062
-52% -$75.4K ﹤0.01% 3367
2025
Q2 		$96.8K Sell
28,726
-3,014
-9% -$11.3K ﹤0.01% 3181
2025
Q1 		$123K Buy
31,740
+1,885
+6% +$8.99K ﹤0.01% 2976
2024
Q4 		$184K Buy
29,855
+19,071
+177% +$110K ﹤0.01% 2687
2024
Q3 		$58K Sell
10,784
-299
-3% -$1.41K ﹤0.01% 2698
2024
Q2 		$37.1K Sell
11,083
-665
-6% -$2.59K ﹤0.01% 2551
2024
Q1 		$47.3K Sell
11,748
-44,492
-79% -$119K ﹤0.01% 2377
2023
Q4 		$149K Buy
+56,240
New +$129K ﹤0.01% 2250

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management's DSGN Position: Q2 2026 in Review

AQR Capital Management increased its Design Therapeutics (DSGN) stake by 174% in Q2 2026, buying an estimated $563K and bringing the position to 71,114 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2989.

AQR Capital Management first reported a position in DSGN in Q4 2023 and has held it in 11 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • AQR Capital Management held 71,114 shares of Design Therapeutics worth $1.03M as of Q2 2026.
  • AQR Capital Management bought 45,157 Design Therapeutics shares in Q2 2026, an estimated $563K.
  • Design Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2989 holding.
  • AQR Capital Management first reported a position in Design Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.